Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
Pharmalot
STAT+
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Biotech venture capitalists have more money than ever to invest. What could possibly go wrong?

  • Kate Sheridan

By Kate Sheridan April 7, 2021

Reprints
money pile
Adobe

There’s more money sloshing around in biotech than ever before.

Over the past year, several trends have converged to create a historic financing environment for startups, full of what industry insiders call “dry powder.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

In an effort to address its missteps during Covid,…
In an effort to address its missteps during Covid, CDC plans an ‘ambitious’ agency overhaul
Medical error: An epidemic compounded by gag laws
Medical error: An epidemic compounded by gag laws
With monkeypox spreading globally, many experts believe the virus…
With monkeypox spreading globally, many experts believe the virus can’t be contained
Bluebird wins U.S. approval for a gene therapy to…
Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder
‘A blind eye’: NIH fails to ensure clinical trial…
‘A blind eye’: NIH fails to ensure clinical trial results are reported, and still funds researchers…
Virtual Event – Biomarkers: The Foundation of Personalized Oncology
Virtual Event – Biomarkers: The Foundation of Personalized Oncology

Recommended Stories